Polymyxin B-induced Bartter syndrome
- PMID: 38702070
- PMCID: PMC11085949
- DOI: 10.1136/bcr-2023-255242
Polymyxin B-induced Bartter syndrome
Abstract
Bartter syndrome is a genetic disorder characterised by chloride-unresponsive metabolic alkalosis, hypokalaemia, hypomagnesaemia and hypercalciuria. While it commonly presents antenatally or in early infancy, sometimes, drugs can induce a state similar to Bartter syndrome in any age group, called acquired Bartter syndrome. Polymyxins and aminoglycosides are the most commonly implicated drugs. Polymyxin B and polymyxin E (popularly known as colistin) are the two chemically similar polymyxins that are commonly used clinically. While colistin is frequently associated with nephrotoxicity, polymyxin B is generally considered less nephrotoxic. This difference is due to the way these two drugs are handled by the kidneys. In this case report, we discuss a middle-aged male who developed Bartter syndrome due to polymyxin B, which resolved on discontinuation of the drug, and re-appeared after its re-introduction later. This case exemplifies the nephrotoxicity caused by polymyxin B and the need for vigilance when using this drug.
Keywords: Adult intensive care; Drugs: infectious diseases; Fluid electrolyte and acid-base disturbances; Unwanted effects / adverse reactions.
© BMJ Publishing Group Limited 2024. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: None declared.
References
-
- Konrad M, Nijenhuis T, Ariceta G, et al. . Diagnosis and management of bartter syndrome: executive summary of the consensus and recommendations from the European rare kidney disease reference network working group for tubular disorders. Kidney Int 2021;99:324–35. 10.1016/j.kint.2020.10.035 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical